MX2018002962A - Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial. - Google Patents

Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial.

Info

Publication number
MX2018002962A
MX2018002962A MX2018002962A MX2018002962A MX2018002962A MX 2018002962 A MX2018002962 A MX 2018002962A MX 2018002962 A MX2018002962 A MX 2018002962A MX 2018002962 A MX2018002962 A MX 2018002962A MX 2018002962 A MX2018002962 A MX 2018002962A
Authority
MX
Mexico
Prior art keywords
ros
compounds
treatment
production
oxygen species
Prior art date
Application number
MX2018002962A
Other languages
English (en)
Inventor
Diolez Philippe
Petitjean Olivier
Marin Frédéric
Detaille Dominique
Original Assignee
OP2 Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OP2 Drugs filed Critical OP2 Drugs
Publication of MX2018002962A publication Critical patent/MX2018002962A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de compuestos para la prevención y el tratamiento de enfermedades cuyo inicio y/o evolución se relaciona con la producción y los efectos de especies reactivas del oxígeno (EOR) de origen mitocondrial.
MX2018002962A 2015-09-08 2016-09-08 Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial. MX2018002962A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215215P 2015-09-08 2015-09-08
EP15184217 2015-09-08
PCT/EP2016/071170 WO2017042267A1 (en) 2015-09-08 2016-09-08 Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Publications (1)

Publication Number Publication Date
MX2018002962A true MX2018002962A (es) 2018-11-09

Family

ID=54065791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002962A MX2018002962A (es) 2015-09-08 2016-09-08 Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial.

Country Status (10)

Country Link
US (2) US10272066B2 (es)
EP (1) EP3347100A1 (es)
JP (1) JP6876047B2 (es)
KR (1) KR20180049019A (es)
CN (1) CN108348781B (es)
AU (1) AU2016319184B2 (es)
CA (1) CA2997855A1 (es)
IL (1) IL257963B (es)
MX (1) MX2018002962A (es)
WO (1) WO2017042267A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180049019A (ko) * 2015-09-08 2018-05-10 오피2 드러그스 미토콘드리아의 반응성 산소 종 (ros) 생성과 관련된 질환 치료용 화합물
FR3063642A1 (fr) * 2017-03-07 2018-09-14 Elodie Petitjean Traitement du glaucome a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
FR3063640B1 (fr) * 2017-03-07 2020-10-09 Elodie Petitjean Traitement de la fibrose pulmonaire a l'aide d'un inhibiteur selectif de la production d'especes reactives de l'oxygene d'origine mitochondriale
WO2018162845A1 (fr) * 2017-03-07 2018-09-13 CHILDS, Marc Prevention des risques associes à un allongement de l'intervalle qt d'origine medicamenteuse à l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
FR3063641A1 (fr) * 2017-03-07 2018-09-14 Olivier Petitjean Prevention des lesions cutanees dues aux uv et des melanomes a l'aide d'un inhibiteur selectif de la production d'especes reactives de l'oxygene d'origine mitochondriale
FR3063644A1 (fr) * 2017-03-07 2018-09-14 Gregoire Petitjean Prevention des effets adverses des statines a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
FR3063643A1 (fr) * 2017-03-07 2018-09-14 Elodie Petitjean Prevention des risques associes a un allongement de l'intervalle qt d'origine medicamenteuse a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
FR3072024A1 (fr) * 2017-10-11 2019-04-12 Olivier Petitjean Prevention et traitement de l’hyperplasie benigne de la prostate a l‘aide d’un inhibiteur selectif de la production d’especes reactives de l’oxygene d’origine mitochondriale
WO2019207553A2 (en) * 2018-04-27 2019-10-31 Joslin Diabetes Center, Inc. Methods and compositions relating to lipokines for treating metabolic disorders
WO2020049166A1 (en) 2018-09-06 2020-03-12 OP2 Drugs Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
US20220000873A1 (en) * 2018-12-12 2022-01-06 Buck Institute For Research On Aging S3qels to protect against intestinal permeability
CN110791475B (zh) * 2019-11-26 2021-07-20 中国农业科学院农产品加工研究所 骨骼肌组织线粒体的提取方法
FR3106978B1 (fr) 2020-02-11 2024-04-26 Olivier Petitjean Utilisation d'une molecule inhibitrice de la production de ros d'origine mitochondriale telle que l'anethole trithione pour traiter la maladie de parkinson
US20240050402A1 (en) * 2020-12-10 2024-02-15 Frédéric MARIN Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN118010601A (zh) * 2024-04-07 2024-05-10 中国医学科学院北京协和医院 一种用于诊断原发性胆汁性胆管炎的系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07118262A (ja) * 1993-10-18 1995-05-09 Mitsui Toatsu Chem Inc 新規１，２−ジチオール−３−チオン誘導体
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
CA2475545A1 (en) * 2002-02-13 2003-08-21 Solvay Pharma Use of anethole dithiolethione in lung cancer chemoprevention
DK1849774T3 (da) * 2005-02-16 2011-10-10 Toa Eiyo Ltd Cyclohepta(b)pyridin-3-carbonylguanidinderivat og farmaceutisk produkt indeholdende samme
JP5240715B2 (ja) * 2006-08-08 2013-07-17 国立大学法人名古屋大学 脂肪組織由来多分化能幹細胞を含有する細胞製剤
JP2010520333A (ja) * 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター 〔１，２〕−ジチオラン部分を含有する抗酸化剤重合体およびその使用
CN102961375B (zh) * 2012-12-05 2015-01-14 苏州大学 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用
KR20180049019A (ko) * 2015-09-08 2018-05-10 오피2 드러그스 미토콘드리아의 반응성 산소 종 (ros) 생성과 관련된 질환 치료용 화합물

Also Published As

Publication number Publication date
CA2997855A1 (en) 2017-03-16
AU2016319184A1 (en) 2018-03-29
AU2016319184B2 (en) 2022-03-31
JP6876047B2 (ja) 2021-05-26
US20180256540A1 (en) 2018-09-13
CN108348781A (zh) 2018-07-31
US10272066B2 (en) 2019-04-30
US11318113B2 (en) 2022-05-03
JP2018534343A (ja) 2018-11-22
KR20180049019A (ko) 2018-05-10
CN108348781B (zh) 2022-02-11
WO2017042267A1 (en) 2017-03-16
EP3347100A1 (en) 2018-07-18
IL257963B (en) 2021-08-31
IL257963A (en) 2018-05-31
US20200276156A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2018002962A (es) Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial.
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
EP3349783C0 (en) COMPOSITIONS AND METHODS ASSOCIATED WITH THE TREATMENT OF DISEASES
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX2018002049A (es) Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
IL269127A (en) Derivatives of desmetylantol triton for the treatment of diseases related to the generation of reactive oxygen species (ROS) of mitochondrial origin
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MY172656A (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
EA201790851A1 (ru) Способы предотвращения, уменьшения и лечения макулодистрофии
NZ707743A (en) Treatment of timber
PH12017501897A1 (en) 2-thiopyrimidinones
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
BR112018004518A2 (pt) compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
GB2546703A (en) Compounds
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases